1. Introduction {#sec1}
===============

Diabetes mellitus refers to a metabolic disorder of multiple etiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat, and protein metabolism resulting from disturbed insulin secretion, insulin action, or both \[[@B1]\]. There are two possible types of diabetes mellitus. Type 1 diabetes, also known as insulin-dependent diabetes, results from an absolute lack of insulin due to autoimmune destruction of the insulin-producing beta cells in the pancreas \[[@B2]\]. Type 2 or non-insulin-dependent diabetes is a metabolic disorder characterized by insulin resistance, relative insulin deficiency, and hyperglycemia \[[@B3]\]. Diabetes mellitus is most closely related to the wasting (Xiao Ke in Chinese pinyin) syndrome as defined by the traditional Chinese medicine diagnostic pattern. Patients with this syndrome typically experience clinical manifestations of emaciation (Xiao in Chinese) and thirst (Ke in Chinese).

According to the WHO diabetes fact sheets, 347 million people in the world have diabetes \[[@B4]\]. In 2004, an estimated 3.4 million people worldwide died from consequences of high blood sugar, and ca. above 80% of diabetes deaths happen in underdeveloped countries \[[@B4]\]. Facing this stark reality, traditional Chinese herbal remedy such as Rhizoma Coptidis (Huang Lian in Chinese pinyin), with its long proven effects for a number of chronic diseases in clinical application and relatively low cost, has been broadly investigated in Asian countries for potential antihyperglycemic effects.

Rhizoma Coptidis (Huang Lian) is the dried rhizome of*Coptis chinensis* Franch,*Coptis deltoidea* C. Y. Cheng et Hsiao or*Coptis teeta* Wall. As first recorded in*Shennong\'s Materia Medica*in the eastern Han dynasty (25--220 AD), the herbal medicine has been prescribed by Chinese herbalists for a variety of illnesses and conditions for more than 2000 years. According to traditional beliefs, Rhizoma Coptidis is cold in nature and bitter in taste and enters the heart, spleen, stomach, liver, gallbladder, and large intestine meridians. It has the function of clearing heat, drying dampness, and purging fire toxins \[[@B5]\]. Main indications include the wasting (Xiao Ke) syndrome, distention, and fullness due to dampness and heat, sickness, acid regurgitation, jaundice, palpitation, diarrhea caused by bacterial infection, high fever, heart-fever hyperactivity, restlessness and insomnia, blood spitting or nose bleeding due to extra heat in the blood, red eyes, and toothache \[[@B5]\].

As early as the Wei and Jin dynasties in the Chinese history (220--589 AD), Rhizoma Coptidis was described as a therapeutic agent for patients suffering from the wasting syndrome. In dynasties that followed, numerous records had been kept in a series of herbal classics of the medicinal use of Rhizoma Coptidis for the wasting syndrome, either alone or combined with other herbs in a formula. This proved the prevalence of the use of Rhizoma Coptidis since ancient times and formed the empirical evidence base for its antidiabetic effects. For example, in the*Miscellaneous Records of Famous Physicians*, compiled around 510 AD, Rhizoma Coptidis was first described as an agent for the wasting syndrome \[[@B6]\]. In the*Newly Revised Materia Medica* compiled during the Tang dynasty (618--907 AD), it was noted that "Huang lian grown in west China is bulky, bitter and good for treating the wasting syndrome" \[[@B7]\]. An analytical review of the Song dynasty (960--1279 AD) medical formulary*Formulas from Benevolent Sages* found that Rhizoma Coptidis was among the top ten most frequently used medicinal herbs in formulas designated for the wasting syndrome \[[@B8]\]. Furthermore, thirteen among the total of 64 herbal formulas for treating the wasting syndrome collected in the*Puji Fang Prescriptions for Universal Relief*, completed around 1406 AD in the Ming dynasty, contained Rhizoma Coptidis \[[@B9]\]. In the most comprehensive medical book of traditional Chinese medicine, the*Compendium of Materia Medica*, published in the same dynasty, it recorded that "Huang lian, steamed with wine, is used for treating emaciation, thirst and excessive excretion of urine" \[[@B9]\].

Modern pharmacological research identified the major chemical constituents of Rhizoma Coptidis to be alkaloids including berberine, coptisine, worenine, palmatine, jatrorrhizine, and epiberberine \[[@B10], [@B11]\]. Among the many constituents, the berberine component is generally considered the primary contributor to its main bioactivities such as the antibiotic, antioxidant, and anti-inflammatory properties \[[@B12]\]. In recent years, berberine and Rhizoma Coptidis extracts have also been reported to have multiple antidiabetic activities such as regulating lipid, balancing glucose metabolism, and improving insulin resistance, and the underlying mechanisms of action have been extensively investigated \[[@B12]\].

In view of this, a comprehensive review of the relevant literatures on the antihyperglycemic effects of Rhizoma Coptidis (or berberine) and the mechanism of actions was conducted. The aim of this study is to give a summary of the existing evidence.

2. Method {#sec2}
=========

In January 2013 two reviewers (Hui Wang and Wei Mu) searched the following Chinese-language electronic databases: Chinese Biomedical Literature Database (CBM, 1980--2013), Chinese Journal Full-Text Database (CNKI, 1980--2013), Weipu Journal Database (VIP, 1989--2013), and Wanfang Data (1990--2013), and three English-language databases: PubMed, EMBASE (1989--2013), and the Cochrane Library. The search terms included "huang lian," "Coptis," "berberine," "hypoglycemic," "diabetes," and "xiaoke" in English or Chinese. These terms were searched as free text in the title or the abstract.

Two reviewers Hui Wang and Wei Mu screened citations identified from electronic searches and retrieved the full texts of relevant studies. Then they summarized records in ancient medical books and the findings of systematic reviews and pharmacological studies on the antihyperglycemic effects of berberine, Rhizoma Coptidis extracts, and other Rhizoma Coptidis-containing agents.

3. Results {#sec3}
==========

3.1. Overview of Systematic Reviews {#sec3.1}
-----------------------------------

Two systematic reviews on the antihyperglycemic effects of berberine were identified. In the first study authored by Dong et al. \[[@B13]\], a total of fourteen randomized controlled trials (RCTs) were included and the results of these studies were subjected to meta-analysis and subgroup analysis. In the later systematic review by Narenqimuge et al. \[[@B14]\], the results of the included ten RCTs were reported descriptively due to significant statistical heterogeneity across studies. The characteristics and results of these two systematic reviews were presented in [Table 1](#tab1){ref-type="table"}.

Drawn upon the above research findings, the isoquinoline-type alkaloid berberine has beneficial effects for blood glucose control in the treatment of type 2 diabetic patients and exhibits efficacy comparable with that of conventional oral hypoglycaemics. No significant statistical difference in the incidence of adverse events was observed between groups. However, the evidence is inconclusive because clinical trials included in the two systematic reviews were of low methodological quality. Therefore, the antihyperglycemic effects of berberine warrant further examination and more rigorously controlled, methodologically sound, and scientifically designed RCTs need to be conducted.

3.2. Review of Pharmacological Research {#sec3.2}
---------------------------------------

A number of animal experiments investigating the antihyperglycemic effects of Rhizoma Coptidis, berberine, or herbal prescriptions in which Rhizoma Coptidis plays a dominant role were identified through electronic searches and careful screening. A summary of the experimental models used and the antidiabetic mechanism of berberine observed in these studies were presented in [Table 2](#tab2){ref-type="table"}. From this table, we found the antidiabetic efficacy of berberine associated most closely with its ability to improve insulin sensitivity, influence insulin secretion, and regulate carbohydrate metabolism, and a majority of the pharmacological experiments focused on these aspects \[[@B16]--[@B62]\]. Moreover, some additional bioactivities of berberine which may facilitate its antidiabetic effects were identified, such as its antioxidant, lipid regulatory, and anti-inflammatory functions as well as its renoprotective properties to prevent diabetes complications. These effects of berberine and the relevant mechanisms were demonstrated in [Table 3](#tab3){ref-type="table"}.

Findings from previous researches showed that the insulin-stimulated glucose uptake by target tissues such as adipocytes and skeletal muscles involved a series of signaling transduction cascades starting from insulin receptor (InsR) via insulin receptor substrate-1 (IRS-1) and phosphatidylinositol 3-kinase (PI-3K) and leading to the translocation of glucose transporter (GLUT4) \[[@B15]\]. From this comprehensive review of the existing pharmacological research on the antihyperglycemic effects of Rhizoma Coptis and its major chemical ingredient berberine, the reviewers summarized a variety of possible mechanisms of action behind its antidiabetic properties, which include the promotion of insulin secretion and release, reparation of pancreatic islets *β*-cells, enhancement of insulin sensitivity, suppression of gluconeogenesis in the liver, promotion of glucose disposal in the periphery, and inhibition of aldose reductase \[[@B16]--[@B62]\]. The mechanisms for Rhizoma Coptis and its component berberine\'s other bioactivities that may facilitate its antidiabetic functions include ameliorating oxidative stress accompanying diabetes, regulating plasma levels of adiponectin and other relevant inflammatory factors, increasing adipocytes glucose transportation and consumption, and modulating metabolism-related protein expression \[[@B63]--[@B77]\].

In addition to the above findings, results from a few studies \[[@B78]--[@B89]\] investigating the effects of Rhizoma Coptidis extracts, Rhizoma Coptidis-dominant couplet medicines, and Rhizoma Coptidis-containing Chinese patent drugs have showed them all to possess certain antihyperglycemic effects. Rhizoma Coptidis-dominant couplet medicines included Rhizoma Coptidis coupled with Panax Ginseng, Rhizoma Coptidis coupled with dried Rehmannia root, and a combination of Rhizoma Coptidis, Astragalus Mongholicus, and Solomonseal Rhizome. Rhizoma Coptidis-containing Chinese patent drug involved Jinlian Jiangtang capsules and Jinqi Jiangtang tablets. Their therapeutic properties, possible mechanisms, and other information were listed in [Table 4](#tab4){ref-type="table"}.

4. Discussion {#sec4}
=============

According to traditional beliefs, Chinese herbal remedy helps recover inner peace and tranquility in the human body with its multiple active constituents taking effects through various mechanisms and pathways. Therefore, the use of Chinese herbal medicines for diabetes treatment or for the prevention of diabetes complications might be generally considered good for the patients\' general well-being, apart from their effectiveness and safety.

The existing evidence profile of the antihyperglycemic effects of Rhizoma Coptidis includes both textual records in ancient herbal classics and findings from animal experiments and systematic reviews of RCTs. Modern research uniformly focuses on berberine, whereas the pharmacological actions of other active ingredients of Rhizoma Coptidis, of single herb remedy, and of Rhizoma Coptidis-dominant couplet medicines and Rhizoma Coptidis-containing patent drug still remain to be investigated.

As was summarized in this review, the antihyperglycemic effects of Rhizoma Coptidis may rely upon drug actions on a variety of targets via multiple pathways. Many animal experiments \[[@B16]--[@B77], [@B78]--[@B89]\] have proposed the scientific rationale for Rhizoma Coptidis, Rhizoma Coptidis-containing agents, or its major component berberine\'s antihyperglycemic effects by identifying possible mechanisms of actions. The widespread use of Rhizoma Coptidis as a routine clinical treatment for diabetes is promising because there is abundant supply, the herb is relatively inexpensive, and it has a good safety profile \[[@B13], [@B14]\]. However, the results of both systematic reviews included in this study need to be interpreted with caution. As large-scale, rigorously controlled, and multicenter randomized controlled clinical studies are still lacking, the clinical efficacy and safety of Rhizoma Coptidis and berberine for antidiabetic use needs further investigation.

Furthermore, there were other issues to consider before Rhizoma Coptidis can be put into extensive clinical use. For instance, the most appropriate drug form and dosage, dose-effect relationship, and drug-drug interactions should be made clear through a series of pharmacological experiments and long-term clinical observations. Also, whether the antihyperglycemic effect is best exerted synergically in a prescription or independently as an active component remains to be investigated. Besides, the possible antidiabetic effects of the other chemical ingredients of Rhizoma Coptidis and the interactions among its various components, as well as the long-term health benefits of its use in diabetic patients, are all problems that need to be addressed in future research.
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###### 

A summary of findings from systematic reviews on the antihyperglycemic effects of berberine.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                Study\                          Study\   Number\   Number\    Results                                                                                                                                                                                                    Conclusion
                                          ID                              Year     of RCTs   of cases                                                                                                                                                                                                              
  --------------------------------------- ------------------------------- -------- --------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  FPG/PPG/HbA1c/FINS/TG/TC/LDL-C/HDL-C    Dong et al. \[[@B13]\]          2012     4         271        Compared with lifestyle changes with or without placebo, berberine plus lifestyle changes showed significantly better hypoglycaemic and antidyslipidemic effects.                                          Trials had poor methodological and reporting quality. The conclusions made were inconclusive and further research is needed.

  FPG/HbA1c/TC/LDL-C                      Dong et al. \[[@B13]\]          2012     7         448        Compared with oral hypoglycaemics (metformin, glipizide, or rosiglitazone) berberine did not demonstrate significantly better hypoglycaemic effects but showed mild antidyslipidemic effects.              

  FPG/PPG/HbA1c/FINS/TG/TC/LDL-C/HDL-C    Dong et al. \[[@B13]\]          2012     6         396        Compared with oral hypoglycaemic drugs, berberine combined with the same oral hypoglycaemics can better control blood sugar in the patients.                                                               

                                                                                                                                                                                                                                                                                                                   

  FBG/2hPBG/HbA1c/LDL-C/HDL-C/TG/TC/BMI   Narenqimuge et al. \[[@B14]\]   2012     10        647        Berberine was effective in lowering FBG but not better than metformin, glipizide, or rosiglitazone. Berberine had no proven effects in decreasing PBG, HbAlc, or BMI and in regulating lipid metabolism.   Trials were at high risk of bias. High-quality trials are needed.

                                                                                                                                                                                                                                                                                                                   

  Adverse events                          Dong et al. \[[@B13]\]          2012     14        1068       Three studies did not report AEs. Three reported no AEs. Three reported adverse events but did not indicate the group in which they occurred. Five reported AEs in the berberine group.                    No significant difference between the treatment and the control group.

                                                                                                                                                                                                                                                                                                                   

  Adverse events                          Narenqimuge et al. \[[@B14]\]   2012     7         435        Seven studies reported that AEs happened in the course of the treatment, mostly gastrointestinal reactions such as constipation and diarrhea. Of them 3 studies reported the number of cases of AEs.       No significant difference between the treatment and the control group.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FPG: fasting blood glucose; PPG: postprandial plasma glucose; HbA1c: hemoglobin A1c; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein; HDL-C: high-density lipoprotein; FINS: fasting insulin; 2hPBG: 2-hour postprandial blood glucose; BMI: body mass index; AEs: adverse events.

###### 

Summary of berberine\'s effects on insulin and glucose metabolism and the mechanism of action \[[@B16]--[@B62]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Experimental model                  Mechanism of action
  ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  T2DM Chinese hamsters               Changed the expression of hepatic peroxisome proliferator-activated receptors and its target genes \[[@B16]\]

  3T3-L1 cells                        Increased glucose uptake in fat cells and inhibited the differentiation of preadipocytes \[[@B17]\]

  Sprague Dawley rats                 Reduced plasma FFA and triglyceride levels and inhibited the expression of liver TNF-*α* \[[@B18]\]

  Sprague Dawley rats                 Increased HNF-4*α* expression \[[@B19]\]

  Wistar rats                         Regulated the expression of endoplasmic reticulum chaperone ORP150 and reduced ER stress \[[@B20]\]

  HepG2 cells                         Regulated AMPK activity to decrease its downstream gluconeogenesis protein expression \[[@B21]\]

  Wistar rats                         Inhibited pancreatic *β*-cell apoptosis by inhibiting ASK1 protein expression \[[@B22]\]

  Wistar rats                         Increased PI-3K p85 and GLUT4 protein expression in skeletal muscles of T2DM rats \[[@B23]\]

  Insulin resistant rat models        Inhibited TNF-*α* secretion and reduced serum free fatty acid level \[[@B24]\]

  Wistar rats                         Increased mRNA expression of adiponectin gene and decreased IRI in T2DM rats \[[@B25]\]

  T2DM Chinese hamsters               Inhibited the expression of PEPCK, 6Pase, and PGC-1*α* by enhancing CYP7A1 and Gck expression induced by the upregulation of LXR*α* expression \[[@B26]\]

  L6 myotubes                         Inhibited fatty acid uptake at least in part by reducing PPAR gamma and FAT/CD36 expression \[[@B27]\]

  L6 rat skeletal muscle cells        Induced InsR gene expression through a protein kinase C (PKC) dependent activation of its promoter. Inhibited PKC abolished BBR-caused InsR promoter activation and InsR mRNA transcription \[[@B28]\]

  Nonalcoholic fatty liver\           Upregulated the mRNA and protein levels of IRS-2 \[[@B29]\]
  disease rat liver                   

  3T3-L1 adipocytes                   Reversed free fatty acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKK*β* \[[@B30]\]

  Cultured HepG2 cells                Attenuated ER stress and improved insulin signal transduction \[[@B31]\]

  Rat skeletal muscle cells           Modulated key molecules in the insulin signaling pathway, leading to increased glucose uptake in insulin-resistant cells \[[@B32]\]

  Insulin resistant rat models        Stimulated AMPK activity \[[@B33]\]

  T2DM hamsters                       Altered the transcriptional programs of the visceral white adipose tissue LXRs, PPARs, and SREBPs \[[@B34]\]

  Diabetic hamsters                   Altered the transcriptional programs of hepatic SREBPs, LXR*α*, and PPAR*α* \[[@B35]\]

  Mouse primary hepatocyte            Upregulated HNF4*α* expression to induce hepatic glucokinase activity \[[@B36]\]

  Mouse primary hepatocyte            Upregulated HNF6 mRNA expression and induced hepatic glucokinase activity \[[@B37]\]

  HepG2 cells                         Increased hepatic glucose consumption \[[@B38]\]

  Wistar rats                         Elevated IRS-1, IRS-2, and p85 mRNA expression in the peripheral tissues \[[@B39]\]

  Sprague Dawley rats                 Increased the content of GLU4 mRNA in skeletal muscles, increased the content of GLUT4 protein in cells, and enhanced insulin activity in the peripheral tissues \[[@B40]\]

  Kunming mice                        Inhibited gluconeogenesis and/or stimulated glycolysis \[[@B41]\]

  Diabetic rat model                  Stimulated GLP-1 release \[[@B42]\]

  Wistar rats                         Regulated INS and GH levels by enhancing SS levels through the hypothalamus-pituitary-pancreatic axis system \[[@B43]\]

  HepG2 cells                         Increased InsR mRNA transcription and protein expression \[[@B44]\]

  Alloxan-induced diabetic mice       Upregulated the activity of Akt \[[@B45]\]

  Wistar rats                         Stimulated GK activity and expression \[[@B46]\]

  3T3-L1 adipocytes and L6 myocytes   Inhibited PTP 1B activity and increased phosphorylation of IR, IRS1, and Akt in 3T3-L1 adipocytes \[[@B47]\]

  Streptozotocin-induced\             Enhanced GLP-1-(7-36) amide secretion \[[@B48]\]
  diabetic rats                       

  Mammalian cells                     Functioned as an agonist of the fatty acid receptor GPR40 \[[@B49]\]

  T2DM rat models                     Lowered serum RBP4 levels and upregulated the expression of tissue GLUT4 protein \[[@B50]\]

  Streptozotocin-induced\             Exhibited inhibitory effects on intestinal disaccharidases and *β*-glucuronidase \[[@B51]\]
  diabetic rats                       

  L6 rat skeletal muscles             Stimulated glucose uptake through the AMP-AMPK-p38 MAPK pathway \[[@B52]\]

  3T3-L1 adipocytes                   Enhanced GLUT1 expression and stimulated the GLUT1-mediated glucose uptake by activating GLUT1 \[[@B53]\]

  Alloxan-induced diabetic\           Upregulated Akt activity via insulin signaling pathways \[[@B54]\]
  C57BL/6 mice                        

  Molecular model                     Inhibited H-PTP 1B \[[@B55]\]

  Streptozotocin-induced\             Involved PKA-dependent pathways \[[@B56]\]
  diabetic rats                       

  Normal animals\                     Acutely inhibited *α*-glucosidase \[[@B57]\]
  (dogs and rats)                     

  Molecular model                     Inhibited DPP IV \[[@B58]\]

  L929 fibroblast cells               Significantly activated GLUT1 transport \[[@B59]\]

  Diabetic rats                       Directly inhibited gluconeogenesis in the liver \[[@B60]\]

  Rat model                           Inhibition of glucose oxidation in mitochondria may contribute to increased AMP/ATP ratio and AMPK activation \[[@B61]\]

  Caco-2 cell line                    Inhibited *α*-glucosidase activity and decreased glucose transport across the intestinal epithelium \[[@B62]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

T2DM: type 2 diabetes mellitus; TNF: tumor necrosis factor; FFA: free fatty acid; HNF: hepatocyte nuclear factor; ER: endoplasmic reticulum; ORP: oxygen-regulated protein; AMPK: AMP-activated protein kinase; ASK: apoptosis signal-regulating kinase; mRNA: messenger RNA; IRI: insulin resistant index; PEPCK: phosphoenolpyruvate carboxylase kinase; PGC-1*α*: peroxisome proliferator-activated receptor-*γ* coactivator 1*α*; CYP7A1: cholesterol 7 *α*-hydroxylase; GCK: glucokinase; PI-3K: phosphatidylinositol 3-kinase; GLUT4: glucose transporter type 4; PPAR: peroxisome proliferator-activated receptor; FAT/CD36: fatty acid translocase; PKC: protein kinase C; BBR: berberine; IKK*β*: inhibitor kappa B kinase *β*; LXRs: liver X receptors; SREBPs: sterol regulatory element binding proteins; IRS: insulin receptor substrates; GLP: glucagon-like peptide; INS: insulin; GH: growth hormone; SS: somatostatin; Akt: protein kinase B; PTP1B: protein tyrosine phosphatase 1B; IR: insulin resistance; GPR40: G protein-coupled receptor 40; RBP4: retinol-binding protein 4; H-PTP 1B: human protein tyrosine phosphatase 1B; DPP IV: dipeptidyl peptidase IV; AMP: adenosine monophosphate; ATP: adenosine triphosphate.

###### 

Summary of other effects of berberine and the mechanism of action \[[@B63]--[@B77]\].

  Effects                                   Experimental model                                                                                                                                                                            Mechanism of action
  ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antioxidative effects                     Type 2 diabetic rats                                                                                                                                                                          Reduced oxidative stress \[[@B63]\]
                                                                                                                                                                                                                                          
  Hypolipidemic effects                     Wistar rats                                                                                                                                                                                   Decreased blood FFA level and enhanced the activity of lipoprotein lipase \[[@B64]\]
  Type 2 diabetic rats                      Increased PPARs and P-TEFb mRNA and protein expression in the adipose tissue. Restored SOD and LPL activity and normalized malondialdehyde, FFA, TNF-*α*, and adiponectin levels \[[@B65]\]   
  3T3-L1 adipocytes                         Increased glucose transport and consumption in 3T3-L1 adipocytes \[[@B66]\]                                                                                                                   
  3T3-L1 adipocytes                         Modulated metabolism-related PPARs expression and differentiation-related P-TEFb expression in adipocytes \[[@B67]\]                                                                          
  3T3-L2 adipocytes                         Activated adenosine monophosphate, activated protein kinase \[[@B68]\]                                                                                                                        
  Diabetic hyperlipidemic and normal rats   Modulated metabolism-related PPAR alpha/delta/gamma protein expression in the liver \[[@B69]\]                                                                                                
                                                                                                                                                                                                                                          
  Anti-inflammatory actions                 Type 2 diabetic rats                                                                                                                                                                          Regulated serum levels of inflammatory factors such as CRP, IL-6, TNF-*α*, and adiponectin \[[@B70]\]
                                                                                                                                                                                                                                          
  Effects on renal injury                   Glomerular mesangial cells                                                                                                                                                                    Inhibited NF-*κ*B activation and the expression of its downstream inflammatory factors to improve ECM accumulation and alleviate inflammatory injury in diabetic kidney \[[@B71]\]
                                                                                                                                                                                                                                          
  Prevention of diabetes complications      Type 2 diabetic rats                                                                                                                                                                          Enhanced vascular smooth muscle activity \[[@B72]\]
                                                                                                                                                                                                                                          
  Renal protective effects                  Rat glomerular mesangial cells                                                                                                                                                                Reduced the accumulation of extracellular matrix components including fibronectin and prevented the activation of the p38 MAPK signaling pathway \[[@B73]\]
  Diabetic rats                             Inhibited glycosylation and exhibited antioxidative effects \[[@B74]\]                                                                                                                        
  Diabetic C57BL/6 mice                     Deactivated the SphK-S1P signaling pathway \[[@B75]\]                                                                                                                                         
  Streptozotocin-induced diabetic rats      Reduced oxidative stress and deactivated aldose reductase \[[@B76], [@B77]\]                                                                                                                  

SOD: superoxide dismutase; LPL: lipoprotein lipase; P-TEFb: positive transcription elongation factor b; CRP: C-reactive protein; IL-6: interleukin-6; NF-*κ*b: nuclear transcription factor-*κ*b; SphK: sphingosine kinase.

###### 

Summary of the antihyperglycemic effects of Rhizoma Coptidis extracts, Rhizoma Coptidis-dominant couplet medicines, or Chinese patent drug and the relevant mechanisms \[[@B78]--[@B89]\].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                                       Effects                                                    Experimental model                                                                                                                                                                                                             Mechanism of actions
  ------------------------------------------------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rhizoma Coptidis decoction                                                                 Antihyperglycemic\                                         Rat brain homogenate                                                                                                                                                                                                           Inhibited pancreatic lipid peroxidation \[[@B78]\]
                                                                                             effects                                                                                                                                                                                                                                                                                   

  Reverse insulin resistance                                                                 Rat model with metabolic syndrome                          Reversed insulin resistance, reduced visceral fat, and upregulated the expression of p-AMPK-A protein \[[@B79]\]                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                       

  Water extracts of Rhizoma Coptidis                                                         Reverse insulin resistance                                 3T3-L1 preadipocytes                                                                                                                                                                                                           Increased glucose uptake in preadipocytes \[[@B80]\]

                                                                                                                                                                                                                                                                                                                                                                                       

  Rhizoma Coptidis coupled with Panax Ginseng                                                Enhance insulin sensitivity                                Type 2 diabetic rats                                                                                                                                                                                                           Lowered TNF-*α* levels, prevented TNF-*α* from inhibiting the expression of GLUT4 in fat and muscle cells, improved autophosphorylation of insulin receptor, inhibited second messenger activation, and promoted lipolysis \[[@B81]\]

  Reverse insulin resistance and regulate glucose and lipid metabolism                       Type 2 diabetic rats                                       Reduced lipotoxicity \[[@B81]\]                                                                                                                                                                                                

  Antihyperglycemic\                                                                         Type 2 diabetic rats                                       Activated PPAR-*γ*, slowed the release of FFA, enhanced the sensitivity of skeletal muscles and the liver to insulin, reduced the exportation of glycogen, and promoted the uptake of glucose in skeletal muscles \[[@B81]\]   
  effects                                                                                                                                                                                                                                                                                                                                                                              

  Reverse insulin resistance                                                                 Type 2 diabetic rats                                       Regulated FBG, INS, FFA, and TNF-*α* levels and improved insulin resistance \[[@B82]\]                                                                                                                                         

  Enhance insulin sensitivity                                                                Type 2 diabetic rats                                       Regulated lipid metabolism and reversed lipotoxicity \[[@B83]\]                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                       

  A combination of Rhizoma Coptidis, Astragalus Mongholicus, and Solomonseal Rhizome         Vascular-protective                                        Wistar rats                                                                                                                                                                                                                    Increased erythrocyte SOD activity and decreased serum MDA level, thereby reducing free radical damages in the hyperglycemic state \[[@B84]\]

                                                                                                                                                                                                                                                                                                                                                                                       

  Sanhuang compound (a mixture of Rhizoma Coptidis, Radix Astragali, and Radix Rehmanniae)   Antihyperglycemic and hypolipidemic effects                Type 2 diabetic rats                                                                                                                                                                                                           Protected and repaired pancreas, enhanced insulin secretion and glycogenesis, and inhibited gluconeogenesis \[[@B85]\]

                                                                                                                                                                                                                                                                                                                                                                                       

  Rhizoma Coptidis coupled with dried Rehmannia root                                         Reverse insulin resistance                                 Type 2 diabetic rats                                                                                                                                                                                                           Decreased the levels of inflammatory cytokine to improve insulin resistance and inhibited apoptosis of islet cells to protect islet *β*-cells \[[@B86]\]

                                                                                                                                                                                                                                                                                                                                                                                       

  Jinlian Jiangtang capsules                                                                 Antihyperglycemic effects                                  Kunming mice                                                                                                                                                                                                                   Promoted insulin release and glucose uptake and improved *β*-cell functioning \[[@B87]\]

                                                                                                                                                                                                                                                                                                                                                                                       

  Jinqi Jiangtang tablets                                                                    Reverse insulin resistance and antihyperglycemic effects   Wistar rats                                                                                                                                                                                                                    Inhibited resistin gene expression \[[@B88]\]

  Antihyperglycemic effects                                                                  3T3-L1 cells and KK-Ay mice                                Activated the AMPK signaling pathway \[[@B89]\]                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MDA: malondialdehyde.
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